Terms: = Leukemia AND TNFAIP3, TNFA1P2, 7128, ENSG00000118503, OTUD7C, MGC138687, MGC104522, A20, MGC138688, P21580 AND Treatment
35 results:
1. Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient treatment of Acute Myeloid leukemia and Overcoming Resistance of FLT3 Inhibitors.
Wang J; Rong Q; Ye L; Fang B; Zhao Y; Sun Y; Zhou H; Wang D; He J; Cui Z; Zhang Q; Kang D; Hu L
J Med Chem; 2024 May; 67(9):7197-7223. PubMed ID: 38655686
[TBL] [Abstract] [Full Text] [Related]
2. Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.
Tatarczuch M; Waltham M; Shortt J; Polekhina G; Hawkes EA; Ho SJ; Trotman J; Brasacchio D; Co M; Li J; Ramakrishnan V; Dunne K; Opat SS; Gregory GP
Blood Adv; 2023 Jul; 7(14):3531-3539. PubMed ID: 36947202
[TBL] [Abstract] [Full Text] [Related]
3. LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2-cFLIP-NF-κB signaling axis.
Wu G; Xu Y; Schultz RD; Chen H; Xie J; Deng M; Liu X; Gui X; John S; Lu Z; Arase H; Zhang N; An Z; Zhang CC
Nat Cancer; 2021 Nov; 2(11):1170-1184. PubMed ID: 35122056
[TBL] [Abstract] [Full Text] [Related]
4. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract] [Full Text] [Related]
5. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
[TBL] [Abstract] [Full Text] [Related]
6. Comparison of alemtuzumab, anti-thymocyte globulin, and post-transplant cyclophosphamide for graft-versus-host disease and graft-versus-leukemia in murine models.
Mashima K; Oh I; Fujiwara K; Izawa J; Takayama N; Nakano H; Kawasaki Y; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Sato K; Ohmine K; Fujiwara SI; Ohno N; Kanda Y
PLoS One; 2021; 16(1):e0245232. PubMed ID: 33428661
[TBL] [Abstract] [Full Text] [Related]
7. A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, tnfaip3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
Chauzeix J; Pastoret C; Donaty L; Gachard N; Fest T; Feuillard J; Rizzo D
Int J Lab Hematol; 2021 Aug; 43(4):683-692. PubMed ID: 33325634
[TBL] [Abstract] [Full Text] [Related]
8. Regulation of cell activation by a20 through STAT signaling in acute lymphoblastic leukemia.
Canh NX; Giang NV; Nghia VX; Sopjani M; Ngan NTT; Hoang NH; Xuan NT
J Recept Signal Transduct Res; 2021 Aug; 41(4):331-338. PubMed ID: 32808859
[TBL] [Abstract] [Full Text] [Related]
9. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract] [Full Text] [Related]
10. Functional role of a long non-coding RNA LIFR-AS1/miR-29a/tnfaip3 axis in colorectal cancer resistance to pohotodynamic therapy.
Liu K; Yao H; Wen Y; Zhao H; Zhou N; Lei S; Xiong L
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2871-2880. PubMed ID: 29807108
[TBL] [Abstract] [Full Text] [Related]
11. Therapeutic Effect of Exogenous Truncated IK Protein in Inflammatory Arthritis.
Choi S; Park H; Jung S; Kim EK; Cho ML; Min JK; Moon SJ; Lee SM; Cho JH; Lee DH; Nam JH
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906466
[TBL] [Abstract] [Full Text] [Related]
12. miR-17-92 promotes leukemogenesis in chronic myeloid leukemia via targeting a20 and activation of NF-κB signaling.
Jia Q; Sun H; Xiao F; Sai Y; Li Q; Zhang X; Yang S; Wang H; Wang H; Yang Y; Wu CT; Wang L
Biochem Biophys Res Commun; 2017 Jun; 487(4):868-874. PubMed ID: 28461114
[TBL] [Abstract] [Full Text] [Related]
13. miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting a20.
Liu Z; Smith KR; Khong HT; Huang J; Ahn EE; Zhou M; Tan M
Oncotarget; 2016 Nov; 7(48):78667-78679. PubMed ID: 27637078
[TBL] [Abstract] [Full Text] [Related]
14. Up-regulated a20 promotes proliferation, regulates cell cycle progression and induces chemotherapy resistance of acute lymphoblastic leukemia cells.
Chen S; Xing H; Li S; Yu J; Li H; Liu S; Tian Z; Tang K; Rao Q; Wang M; Wang J
Leuk Res; 2015 Sep; 39(9):976-83. PubMed ID: 26159495
[TBL] [Abstract] [Full Text] [Related]
15. tnfaip3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy.
Matsuzawa Y; Oshima S; Takahara M; Maeyashiki C; Nemoto Y; Kobayashi M; Nibe Y; Nozaki K; Nagaishi T; Okamoto R; Tsuchiya K; Nakamura T; Ma A; Watanabe M
Autophagy; 2015; 11(7):1052-62. PubMed ID: 26043155
[TBL] [Abstract] [Full Text] [Related]
16. α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics.
Marcondes AM; Karoopongse E; Lesnikova M; Margineantu D; Welte T; Dinarello CA; Hockenbery D; Janciauskiene S; Deeg HJ
Blood; 2014 Oct; 124(18):2881-91. PubMed ID: 25224412
[TBL] [Abstract] [Full Text] [Related]
17. Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice.
Ruffini PA; Os A; Dolcetti R; Tjønnfjord GE; Munthe LA; Bogen B
J Transl Med; 2014 Jul; 12():207. PubMed ID: 25059102
[TBL] [Abstract] [Full Text] [Related]
18. Differential effects of antofine N-oxide on solid tumor and leukemia cells.
Bour T; Yang X; Li W; Bernardin F; Kaoma T; Muller A; Vallar L; Steinmetz A
Anticancer Agents Med Chem; 2014; 14(10):1315-23. PubMed ID: 24962072
[TBL] [Abstract] [Full Text] [Related]
19. Latexin is down-regulated in hematopoietic malignancies and restoration of expression inhibits lymphoma growth.
Liu Y; Howard D; Rector K; Swiderski C; Brandon J; Schook L; Mehta J; Bryson JS; Bondada S; Liang Y
PLoS One; 2012; 7(9):e44979. PubMed ID: 23028717
[TBL] [Abstract] [Full Text] [Related]
20. Involvement of IRAKs and TRAFs in anti-β₂GPI/β₂GPI-induced tissue factor expression in THP-1 cells.
Xu G; Wen H; Zhou H; Guo D; Zhou F; Chen D; Xie H; Wang T; Wang H
Thromb Haemost; 2011 Dec; 106(6):1158-69. PubMed ID: 21901230
[TBL] [Abstract] [Full Text] [Related]
[Next]
